Log in

Artemis Therapeutics Stock Price, News & Analysis (OTCMKTS:ATMS)

0.00 (0.00 %)
(As of 10/21/2019 01:35 AM ET)
Today's Range
Now: $0.15
50-Day Range
MA: $0.16
52-Week Range
Now: $0.15
Average Volume26 shs
Market Capitalization$772,500.00
P/E RatioN/A
Dividend YieldN/A
Artemis Therapeutics Inc., a biopharmaceutical company, engages in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company's lead product candidate is Artemisone, an orally-administered 10-alpha-amino artemisinin derivative with antiviral and antiparasitic properties. It focuses on advancing Artemisone as an antiparasitic treatment for patients infected with Plasmodium falciparum; and as an antiviral agent to address unmet clinical needs in immunocompromised patients infected with human cytomegalovirus and other viral or infectious diseases. The company has license agreement with Hadasit Medical Research Services and Development Ltd., Hadassah Medical Organization, and Hong Kong University of Science and Technology R and D Corporation Limited for the development of Artemisone. Artemis Therapeutics Inc. was incorporated in 1997 and is based in New York, New York. Artemis Therapeutics Inc. is a subsidiary of Tonak Ltd.

Industry, Sector and Symbol

Industry Miscellaneous chemical products
Current SymbolOTCMKTS:ATMS



Sales & Book Value

Annual SalesN/A
Book Value($0.06) per share


Net Income$-510,000.00


Market Cap$772,500.00
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive ATMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATMS and its competitors with MarketBeat's FREE daily newsletter.

Artemis Therapeutics (OTCMKTS:ATMS) Frequently Asked Questions

What is Artemis Therapeutics' stock symbol?

Artemis Therapeutics trades on the OTCMKTS under the ticker symbol "ATMS."

When is Artemis Therapeutics' next earnings date?

Artemis Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Artemis Therapeutics.

Has Artemis Therapeutics been receiving favorable news coverage?

News stories about ATMS stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Artemis Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Artemis Therapeutics.

Who are some of Artemis Therapeutics' key competitors?

Who are Artemis Therapeutics' key executives?

Artemis Therapeutics' management team includes the folowing people:
  • Mr. Chanan Morris, Chief Financial Officer (Age 53)
  • Prof. Dana Wolf, Chief Scientific Officer (Age 62)
  • Mr. Brian M. Culley, Chief Exec. Officer (Age 48)

How do I buy shares of Artemis Therapeutics?

Shares of ATMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Artemis Therapeutics' stock price today?

One share of ATMS stock can currently be purchased for approximately $0.15.

How big of a company is Artemis Therapeutics?

Artemis Therapeutics has a market capitalization of $772,500.00. View Additional Information About Artemis Therapeutics.

What is Artemis Therapeutics' official website?

The official website for Artemis Therapeutics is http://www.artemis-therapeutics.com/.

How can I contact Artemis Therapeutics?

Artemis Therapeutics' mailing address is 18 EAST 16TH STREET SUITE 307, NEW YORK NY, 10003. The company can be reached via phone at 646-233-1454 or via email at [email protected]

MarketBeat Community Rating for Artemis Therapeutics (OTCMKTS ATMS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  29 (Vote Underperform)
Total Votes:  53
MarketBeat's community ratings are surveys of what our community members think about Artemis Therapeutics and other stocks. Vote "Outperform" if you believe ATMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATMS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Featured Article: Sell-Side Analysts

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel